Characterization of Fosfomycin Resistance and Molecular Epidemiology Among Carbapenem-resistant Klebsiella Pneumoniae Strains from Two Tertiary Hospitals in China

Overview

Journal BMC Microbiol

Publisher Biomed Central

Specialty Microbiology

Date 2021 Apr 11

PMID 33838639

Citations 7

Authors

Haichen Wang

Changhang Min

Jun Li

Ting Yu

Yongmei Hu

Qingya Dou

Mingxiang Zou

Affiliations

Soon will be listed here.

Abstract

Background: Fosfomycin has been proven to be a vital choice to treat infection caused by multidrug resistance bacteria, especially carbapenem-resistant Klebsiella pneumoniae (CRKP). However, fosfomycin resistant cases has been reported gradually. In this study, we reported the fosfomycin-resistant rate in CRKP strains and further revealed the molecular mechanisms in resistance gene dissemination.

Results: A total of 294 non-duplicated CRKP strains were collected. And 55 fosfomyin-resistant strains were detected, 94.5% of which were clustered to sequence type (ST) 11 by PCR followed up sequencing. PFGE further revealed two major groups and four singletons. The positive rates of genes responsible to fosfomycin and carbapenem resistance were 81.8% (fosA3), 12.7% (fosA5) and 94.5% (bla), respectively. Genomic analysis confirmed insertion sequence (IS) 26 was the predominant structure surrounding fosA3. The fosA3 genes in six isolates were located on plasmids which were able to transfer to E. coli J53 recipient cells by means of conjugation.

Conclusions: Although the resistant rate of CRKP to fosfomycin is relatively low in our area, considering its gene is located on transferrable plasmid and inserted in IS structure, continuous monitoring is still needed.

Citing Articles

FosA3 emerging in clinical carbapenemase-producing .

Mattioni Marchetti V, Venturelli I, Cassetti T, Meschiari M, Migliavacca R, Bitar I Front Cell Infect Microbiol. 2024; 14:1447933.

PMID: 39247055 PMC: 11378647. DOI: 10.3389/fcimb.2024.1447933.

Polyclonal Spread of Fosfomycin Resistance among Carbapenemase-Producing Members of the in the Czech Republic.

Mattioni Marchetti V, Kraftova L, Finianos M, Sourenian T, Hrabak J, Bitar I Microbiol Spectr. 2023; 11(3):e0009523.

PMID: 37098942 PMC: 10269928. DOI: 10.1128/spectrum.00095-23.

Risk factors and molecular epidemiology of fecal carriage of carbapenem resistant Enterobacteriaceae in patients with liver disease.

Tian F, Li Y, Wang Y, Yu B, Song J, Ning Q Ann Clin Microbiol Antimicrob. 2023; 22(1):10.

PMID: 36710337 PMC: 9884424. DOI: 10.1186/s12941-023-00560-8.

Molecular Epidemiology of Carbapenem-Resistant in a Tertiary Hospital in Northern China.

Wang S, Dong H, Wang M, Ma W, Cheng Y, Zhou J Can J Infect Dis Med Microbiol. 2022; 2022:2615753.

PMID: 36510603 PMC: 9741528. DOI: 10.1155/2022/2615753.

Co-Occurrence of β-Lactam and Aminoglycoside Resistance Determinants among Clinical and Environmental Isolates of and : A Genomic Approach.

Altayb H, Elbadawi H, Alzahrani F, Baothman O, Kazmi I, Nadeem M Pharmaceuticals (Basel). 2022; 15(8).

PMID: 36015159 PMC: 9416466. DOI: 10.3390/ph15081011.

References

Carattoli A, Bertini A, Villa L, Falbo V, Hopkins K, Threlfall E . Identification of plasmids by PCR-based replicon typing. J Microbiol Methods. 2005; 63(3):219-28. DOI: 10.1016/j.mimet.2005.03.018. View

Liu P, Chen S, Wu Z, Qi M, Li X, Liu C . Mechanisms of fosfomycin resistance in clinical isolates of carbapenem-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2020; 22:238-243. DOI: 10.1016/j.jgar.2019.12.019. View

Lee C, Lee J, Park K, Kim Y, Jeong B, Lee S . Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection Methods. Front Microbiol. 2016; 7:895. PMC: 4904035. DOI: 10.3389/fmicb.2016.00895. View

Hou J, Huang X, Deng Y, He L, Yang T, Zeng Z . Dissemination of the fosfomycin resistance gene fosA3 with CTX-M β-lactamase genes and rmtB carried on IncFII plasmids among Escherichia coli isolates from pets in China. Antimicrob Agents Chemother. 2012; 56(4):2135-8. PMC: 3318358. DOI: 10.1128/AAC.05104-11. View

Takahata S, Ida T, Hiraishi T, Sakakibara S, Maebashi K, Terada S . Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli. Int J Antimicrob Agents. 2010; 35(4):333-7. DOI: 10.1016/j.ijantimicag.2009.11.011. View

Fu Y, Du X, Ji J, Chen Y, Jiang Y, Yu Y . Epidemiological characteristics and genetic structure of blaNDM-1 in non-baumannii Acinetobacter spp. in China. J Antimicrob Chemother. 2012; 67(9):2114-22. DOI: 10.1093/jac/dks192. View

Pakhomova S, Rife C, Armstrong R, Newcomer M . Structure of fosfomycin resistance protein FosA from transposon Tn2921. Protein Sci. 2004; 13(5):1260-5. PMC: 2286755. DOI: 10.1110/ps.03585004. View

Gupta K, Hooton T, Naber K, Wullt B, Colgan R, Miller L . International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011; 52(5):e103-20. DOI: 10.1093/cid/ciq257. View

Reyes J, Aguilar A, Caicedo A . Carbapenem-Resistant : Microbiology Key Points for Clinical Practice. Int J Gen Med. 2019; 12:437-446. PMC: 6886555. DOI: 10.2147/IJGM.S214305. View

10.

Li G, Zhang Y, Bi D, Shen P, Ai F, Liu H . First report of a clinical, multidrug-resistant Enterobacteriaceae isolate coharboring fosfomycin resistance gene fosA3 and carbapenemase gene blaKPC-2 on the same transposon, Tn1721. Antimicrob Agents Chemother. 2014; 59(1):338-43. PMC: 4291370. DOI: 10.1128/AAC.03061-14. View

11.

Ho P, Chan J, Lo W, Lai E, Cheung Y, Lau T . Prevalence and molecular epidemiology of plasmid-mediated fosfomycin resistance genes among blood and urinary Escherichia coli isolates. J Med Microbiol. 2013; 62(Pt 11):1707-1713. DOI: 10.1099/jmm.0.062653-0. View

12.

Golla V, Sans-Serramitjana E, Pothula K, Benier L, Bafna J, Winterhalter M . Fosfomycin Permeation through the Outer Membrane Porin OmpF. Biophys J. 2019; 116(2):258-269. PMC: 6350074. DOI: 10.1016/j.bpj.2018.12.002. View

13.

Aghamali M, Sedighi M, Zahedi Bialvaei A, Mohammadzadeh N, Abbasian S, Ghafouri Z . Fosfomycin: mechanisms and the increasing prevalence of resistance. J Med Microbiol. 2018; 68(1):11-25. DOI: 10.1099/jmm.0.000874. View

14.

Rios E, Lopez M, Rodriguez-Avial I, Culebras E, Picazo J . Detection of Escherichia coli ST131 clonal complex (ST705) and Klebsiella pneumoniae ST15 among faecal carriage of extended-spectrum β-lactamase- and carbapenemase-producing Enterobacteriaceae. J Med Microbiol. 2016; 66(2):169-174. DOI: 10.1099/jmm.0.000399. View

15.

Karageorgopoulos D, Wang R, Yu X, Falagas M . Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens. J Antimicrob Chemother. 2011; 67(2):255-68. DOI: 10.1093/jac/dkr466. View

16.

Villa L, Garcia-Fernandez A, Fortini D, Carattoli A . Replicon sequence typing of IncF plasmids carrying virulence and resistance determinants. J Antimicrob Chemother. 2010; 65(12):2518-29. DOI: 10.1093/jac/dkq347. View

17.

Wolter D, Kurpiel P, Woodford N, Palepou M, Goering R, Hanson N . Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother. 2008; 53(2):557-62. PMC: 2630594. DOI: 10.1128/AAC.00734-08. View

18.

Li J, Zou M, Dou Q, Hu Y, Wang H, Yan Q . Characterization of clinical extensively drug-resistant Pseudomonas aeruginosa in the Hunan province of China. Ann Clin Microbiol Antimicrob. 2016; 15(1):35. PMC: 4877936. DOI: 10.1186/s12941-016-0148-y. View

19.

Lu P, Hsieh Y, Lin J, Huang J, Yang T, Lin L . Characterisation of fosfomycin resistance mechanisms and molecular epidemiology in extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates. Int J Antimicrob Agents. 2016; 48(5):564-568. DOI: 10.1016/j.ijantimicag.2016.08.013. View

20.

Huang L, Cao M, Hu Y, Zhang R, Xiao Y, Chen G . Prevalence and mechanisms of fosfomycin resistance among KPC-producing Klebsiella pneumoniae clinical isolates in China. Int J Antimicrob Agents. 2020; 57(1):106226. DOI: 10.1016/j.ijantimicag.2020.106226. View